Related Experiment Video
Updated: May 12, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Erdheim-Chester disease
Julien Haroche1, Laurent Arnaud, Fleur Cohen-Aubart
1Department of Internal Medicine, French Reference Center for Rare Autoimmune and Systemic Diseases, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France. julien.haroche@psl.aphp.fr
Insights
Erdheim-Chester disease (ECD), a rare histiocytosis, is diagnosed via tissue biopsy. BRAFV600E mutation and central nervous system involvement impact prognosis, while interferon alpha and vemurafenib show therapeutic promise.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Erdheim-Chester disease (ECD) is a rare non-Langerhans' cell histiocytosis.
- Central nervous system involvement is a critical prognostic indicator in ECD.
- Histiocytes, foamy and CD68+ CD1a-, are diagnostic hallmarks via tissue biopsy.
Purpose of the Study:
- To summarize diagnostic criteria for Erdheim-Chester disease.
- To highlight prognostic factors including CNS involvement.
- To review current and emerging therapeutic strategies for ECD.
Main Methods:
- Review of diagnostic criteria for ECD.
- Analysis of prognostic factors in ECD patient cohorts.
- Evaluation of therapeutic outcomes for interferon alpha and vemurafenib.
Main Results:
- ECD diagnosis relies on characteristic histiocytes in tissue biopsies.
- BRAFV600E mutation occurs in over 50% of ECD cases.
- Interferon alpha improves survival; vemurafenib shows benefit in BRAFV600E-mutated, refractory ECD.
Conclusions:
- Early diagnosis and management of ECD are crucial.
- Targeting BRAFV600E mutation with vemurafenib offers a promising therapeutic avenue for severe ECD.
- Further research into ECD pathogenesis and treatment is warranted.
Abstract:
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans' cell histiocytosis. Diagnosis of ECD is based on the identification in tissue biopsy of histiocytes, which are typically foamy and immunostain for CD68+ CD1a-. Central nervous system involvement is a major prognostic factor in ECD. Interferon alpha may be the best first-line therapy and significantly improves survival of ECD. The BRAFV600E mutation is found in more than 50% of cases. Vemurafenib has been used for a small number of patients harbouring this mutation; inhibition of BRAF activation by vemurafenib was highly beneficial in these cases of severe multisystemic and refractory ECD.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Hypersensitivity Reactions: Immune-Complex Reactions
Endocarditis II: Clinical Features of Infective Endocarditis
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Other Disorders of Digestive System

